GETI.B

210

+0.43%↑

BIOAB

320.2

-0.12%↓

EKTA.B

55.45

-0.72%↓

VITR

138

-0.5%↓

AMBEA

137.1

+2.01%↑

GETI.B

210

+0.43%↑

BIOAB

320.2

-0.12%↓

EKTA.B

55.45

-0.72%↓

VITR

138

-0.5%↓

AMBEA

137.1

+2.01%↑

GETI.B

210

+0.43%↑

BIOAB

320.2

-0.12%↓

EKTA.B

55.45

-0.72%↓

VITR

138

-0.5%↓

AMBEA

137.1

+2.01%↑

GETI.B

210

+0.43%↑

BIOAB

320.2

-0.12%↓

EKTA.B

55.45

-0.72%↓

VITR

138

-0.5%↓

AMBEA

137.1

+2.01%↑

GETI.B

210

+0.43%↑

BIOAB

320.2

-0.12%↓

EKTA.B

55.45

-0.72%↓

VITR

138

-0.5%↓

AMBEA

137.1

+2.01%↑

Home・Elenco Azioni・Camurus AB

Camurus AB

Aperta

609 -0.41

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

608

Massimo

610.5

Metriche Chiave
By Trading Economics
Entrata	-99M 193M
Vendite	-108M 567M
P/E Media del settore	45.821 77.671
EPS	3.19
Margine di Profitto	33.972
Dipendenti	280
EBITDA	-62M 253M

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-492M 36B
Apertura precedente	609.41
Chiusura precedente	609

Camurus AB Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 dic 2025, 22:53 UTC

Acquisizioni, Fusioni, Takeovers

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

13 dic 2025, 00:04 UTC

Acquisizioni, Fusioni, Takeovers

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

14 dic 2025, 23:46 UTC

Discorsi di Mercato

Gold Edges Higher Amid Some Tailwinds -- Market Talk

14 dic 2025, 23:36 UTC

Discorsi di Mercato

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

14 dic 2025, 22:38 UTC

Acquisizioni, Fusioni, Takeovers

Fortescue to Take Full Control of US$101M Copper Miner Alta

14 dic 2025, 22:02 UTC

Acquisizioni, Fusioni, Takeovers

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

14 dic 2025, 22:01 UTC

Acquisizioni, Fusioni, Takeovers

Fortescue: Alta Owns the Canariaco Project in Northern Peru

14 dic 2025, 22:01 UTC

Acquisizioni, Fusioni, Takeovers

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

14 dic 2025, 22:00 UTC

Acquisizioni, Fusioni, Takeovers

Fortescue: Agreement Implies Total Equity Value of C$139 Million

14 dic 2025, 22:00 UTC

Acquisizioni, Fusioni, Takeovers

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

14 dic 2025, 21:59 UTC

Acquisizioni, Fusioni, Takeovers

Fortescue to Acquire Remaining 64% of Alta Copper

14 dic 2025, 17:00 UTC

Utili

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

14 dic 2025, 08:30 UTC

Acquisizioni, Fusioni, Takeovers

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

13 dic 2025, 16:48 UTC

Acquisizioni, Fusioni, Takeovers

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 dic 2025, 08:00 UTC

Acquisizioni, Fusioni, Takeovers

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 dic 2025, 07:00 UTC

Acquisizioni, Fusioni, Takeovers

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13 dic 2025, 00:24 UTC

Acquisizioni, Fusioni, Takeovers

Want a Piece Of SpaceX? -- Barrons.com

12 dic 2025, 23:49 UTC

Acquisizioni, Fusioni, Takeovers

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12 dic 2025, 22:52 UTC

Discorsi di Mercato

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12 dic 2025, 22:32 UTC

Utili

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12 dic 2025, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

12 dic 2025, 20:45 UTC

Utili

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12 dic 2025, 20:41 UTC

Discorsi di Mercato

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12 dic 2025, 20:20 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12 dic 2025, 19:23 UTC

Utili

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12 dic 2025, 18:35 UTC

Acquisizioni, Fusioni, Takeovers

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12 dic 2025, 18:33 UTC

Acquisizioni, Fusioni, Takeovers

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12 dic 2025, 18:31 UTC

Discorsi di Mercato

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12 dic 2025, 17:49 UTC

Utili

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12 dic 2025, 17:34 UTC

Acquisizioni, Fusioni, Takeovers

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Confronto tra pari

Modifica del prezzo

Camurus AB Previsione

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.